OM:GETI BMedical Equipment
Getinge’s 2025 Report Highlights Key CE And MDR Progress For Cardiosave
Getinge has released its 2025 Annual Report, highlighting key regulatory milestones for its cardiovascular devices.
The company reports that the CE certificate for its intra aortic balloon pump Cardiosave has been reinstated.
Getinge has also secured several new MDR approvals, signaling progress in meeting updated European regulatory requirements.
For investors following OM:GETI B, these regulatory updates come at a share price of SEK187.0 and a mixed return profile. The stock is up 2.5%...